Researchers behind Alzheimer's study: GLP-1 drugs show great promise

Armed with data from a phase II trial testing the efficiency of Novo Nordisk's liraglutide on Alzheimer's patients, scientists say the given drug class shows great promise for combating the disease – even though the market shows disappointment on Novo's behalf.

Photo: George Frey/Reuters/Ritzau Scanpix

Few ailments have frustrated medical science and the pharmaceutical industry for years on end in the way Alzheimer's has, as many have tried – and failed – to develop just one efficient treatment for the disease.

For this reason, the so-called Elad trial, which tests Novo Nordisk's liraglutide, which by the name of Victoza is already a well-established treatment for type II diabetes, as a treatment for Alzheimer's disease.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles